Novo Nordisk | NVO - Ebitda


Novo Nordisk reported DKK37.36B in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
ANI Pharmaceuticals USD 71.6M 6.69M Jun/2026
Aurora Cannabis CAD 3.7M 14.78M Mar/2026
Bausch Health Companies USD 1.08B 238M Jun/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Canopy Growth CAD -137M 134.13M Mar/2026
Corcept Therapeutics USD -49M 53.2M Mar/2026
Drreddys Laboratories INR 8.63B 12.96B Mar/2026
Eli Lilly USD 10.29B 1.86B Mar/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Merck USD -1.54B 7.84B Mar/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Novo Nordisk DKK 37.36B 2.64B Jun/2026
Novo Nordisk DKK 37.36B 31.84B Jun/2026
Pacira USD 48.67M 8.43M Jun/2026
Perrigo USD 141.6M 1.34B Mar/2026
Phibro Animal Health USD 68.1M 6.2M Dec/2025
Prestige Brands USD 61.24M 23.31M Jun/2026
Sanofi EUR 3.69B 375M Jun/2026
Supernus Pharmaceuticals USD 31.6M 2.37M Jun/2026
Zoetis USD 939M 0 Mar/2026